Protein molecules with nucleotide transferase activity and their uses in the preparation of CBASS defense system antagonists, engineered bacteriophages, and antibacterial agents.

By screening and preparing the anti-CBASS protein CsNTase with nucleotide transferase activity, the problem of low infection and amplification efficiency of bacteriophages under the activation of the host CBASS defense system was solved, and the infection and amplification capabilities in the host of the CBASS defense system were improved, which can be applied to the fields of microbial control and food safety control.

CN123107960APending Publication Date: 2026-11-17THIRD INSTITUTE OF OCEANOGRAPHY STATE OCEANI C ADMINISTRATION
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611611530.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-19
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

The activation of the CBASS defense system within the host cell by bacteriophages leads to low infection and amplification efficiency, and existing technologies are unable to effectively counteract the host's CBASS defense system.

Method used

A protein molecule with nucleotide transferase activity (anti-CBASS protein CsNTase) was screened and prepared to antagonize the CBASS defense system by interfering with the immune signal recognition and activation of the host cyclic nucleotide sensing domain and downstream effector modules.

Benefits of technology

This enhances the infection and amplification capabilities of bacteriophages in hosts carrying the CBASS defense system, thereby improving the effectiveness of bacteriophages in microbial control, food safety control, and industrial fermentation pollution remediation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107960A_ABST
    Figure CN123107960A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biotechnology and discloses a protein molecule with nucleotidyltransferase activity and its use in the preparation of CBASS defense system antagonists, engineered bacteriophages, and antibacterial agents. Specifically, the protein molecule includes the amino acid fragment shown in SEQ ID NO:1, which can antagonize the CBASS defense system, effectively helping bacteriophages overcome host defense restrictions, and improving the infection and amplification capabilities of bacteriophages in microorganisms carrying the CBASS defense system. It has excellent application prospects in fields such as microbial control, food safety control, industrial fermentation pollution control, and research on CBASS defense mechanisms and viral immune escape mechanisms.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biotechnology and discloses a protein molecule with nucleotide transferase activity and its use in the preparation of CBASS defense system antagonists, engineered bacteriophages and antibacterial agents. Background Technology

[0002] In recent years, the problem of antibiotic-resistant bacteria has become increasingly prominent, limiting the effectiveness of traditional antibiotics in bacterial infection treatment, food safety control, agricultural disease prevention and control, and industrial microbial contamination control. Bacteriophages, capable of specifically recognizing and lysing bacteria, are considered a promising non-antibiotic antibacterial tool. However, the practical application of bacteriophages still faces several technical obstacles, one significant limiting factor being the host bacteria's own anti-phage defense system. Even if bacteriophages can adsorb and enter host cells, the host defense system may still be activated early in viral replication, causing infected cells to become dormant, die, or block viral replication, thereby reducing the efficiency of bacteriophage amplification and spread.

[0003] Cyclic-oligonucleotide-based anti-phage signaling systems (CBASS) are an important prokaryotic defense system against bacteriophages. This system is activated upon host infection by a bacteriophage, with its core CD-NTase enzyme producing 3',3'-cGAMP and 2',3'-cGAMP cyclic nucleotide second messenger molecules. These small molecule signals can be further recognized by cyclic nucleotide sensing domains, activating downstream effector proteins and triggering a suicide defense response in infected cells to block bacteriophage transmission.

[0004] Therefore, for bacterial hosts carrying the CBASS defense system, it is necessary to consider whether bacteriophages can overcome the CBASS defense barrier within the host cell. Thus, obtaining an anti-CBASS protein that antagonizes the CBASS defense system could help bacteriophages overcome host defense limitations, enhancing their infection and amplification capabilities in bacteria carrying the CBASS defense system. This has promising applications in research on virus-host interactions and the engineering of bacteriophages. Summary of the Invention

[0005] The primary objective of this invention is to provide a protein molecule with nucleotidyltransferase activity, which is a highly promising active substance for antagonizing the CBASS defense system.

[0006] A second objective of this invention is to provide a nucleic acid molecule.

[0007] A third object of the present invention is to provide the use of the above-mentioned protein or nucleic acid molecules in the preparation of CBASS defense system antagonists.

[0008] A fourth objective of this invention is to provide a CBASS defense system antagonist.

[0009] The fifth objective of this invention is to provide the application of the aforementioned protein molecules, nucleic acid molecules, or CBASS defense system antagonists in the construction or modification of engineered bacteriophages capable of antagonizing the CBASS defense system.

[0010] The sixth object of the present invention is to provide the use of the above-mentioned protein molecules, nucleic acid molecules or CBASS defense system antagonists in the preparation of antibacterial agents.

[0011] The seventh objective of this invention is to provide an antibacterial preparation.

[0012] Specifically, the protein molecule provided by the present invention includes the amino acid fragment shown in SEQ ID NO:1.

[0013] The nucleic acid molecule provided by this invention includes a nucleotide fragment encoding the above-mentioned protein molecule.

[0014] Furthermore, the sequence of the nucleotide fragment encoding the protein molecule is shown in SEQ ID NO:2.

[0015] This invention provides the use of the above-mentioned protein or nucleic acid molecules in the preparation of CBASS defense system antagonists, wherein the protein molecules have nucleotide transferase activity.

[0016] The CBASS defense system antagonist provided by this invention includes the aforementioned protein molecules or nucleic acid molecules.

[0017] This invention provides the use of the aforementioned protein molecules, nucleic acid molecules, or CBASS defense system antagonists in the construction or modification of engineered bacteriophages capable of antagonizing the CBASS defense system.

[0018] This invention provides the use of the above-mentioned protein molecules, nucleic acid molecules, or CBASS defense system antagonists in the preparation of antibacterial agents.

[0019] Furthermore, the antibacterial agent is used to inhibit and / or kill microorganisms containing the CBASS defense system.

[0020] The antibacterial agents provided by this invention include the aforementioned protein molecules, nucleic acid molecules, or CBASS defense system antagonists.

[0021] Furthermore, the antibacterial agent includes a bacteriophage, which includes one or more of T4 bacteriophage, T5 bacteriophage, and T7 bacteriophage.

[0022] Furthermore, the antibacterial agent includes a delivery carrier for delivering protein molecules, nucleic acid molecules, or CBASS defense system antagonists into the cells of microorganisms containing a CBASS defense system; the delivery carrier includes one or more of lipid nanoparticles, polymer nanoparticles, and inorganic nanomaterials.

[0023] Beneficial effects: The protein molecule provided by this invention specifically includes the amino acid fragment shown in SEQ ID NO:1, which can effectively antagonize the CBASS defense system, help bacteriophages overcome host defense restrictions, and improve the infection and lysis capabilities of bacteriophages in microorganisms carrying the CBASS defense system. It has excellent application prospects in fields such as microbial control, food safety control, industrial fermentation pollution control, and research on CBASS defense mechanisms and viral immune escape mechanisms. Attached Figure Description

[0024] Figure 1 This is a structural alignment diagram of the anti-CBASS protein CsNTase and its corresponding dbAPIS reference protein provided in the embodiments of the present invention. Figure 2 The figure shows the experimental results of the anti-CBASS anti-defense activity test of the anti-CBASS protein CsNTase provided in the embodiments of the present invention. Detailed Implementation

[0025] The inventors of this invention, based on obtaining an anti-CBASS protein capable of antagonizing the CBASS defense system, used viruses from deep-sea cold seep environments characterized by low temperature, high pressure, darkness, and abundance of reducing substances such as methane and hydrogen sulfide as the target for analysis. Utilizing bioinformatics methods—through comparison with anti-defense protein databases, sequence feature analysis, protein three-dimensional structural similarity, and functional verification—they creatively screened a protein molecule with potential nucleotide transferase activity (NTase) from deep-sea cold seep viruses. This protein molecule is structurally related to existing known anti-CBASS proteins but has low sequence similarity, exhibiting a good ability to antagonize the CBASS defense system. It has application value in fields such as phage engineering, microbial control, food safety control, industrial fermentation pollution control, and research on prokaryotic antiviral defense mechanisms. Based on this, the technical solution of this invention was obtained.

[0026] The present invention provides a protein molecule comprising the amino acid fragment shown in SEQ ID NO:1.

[0027] In this invention, the protein molecule structure includes an NTase characteristic motif, possesses potential nucleotide transferase activity, and may antagonize the CBASS defense system by interfering with the recognition and activation of innate immune signals by the host cyclic nucleotide sensing domain or downstream effector modules.

[0028] In this invention, the protein molecule structure preferably also includes a functional fragment. The functional fragment refers to a tag introduced into the protein molecule for specific purposes such as purification, detection, and solubilization without affecting the functional activity of the protein molecule. This is a commonly used technical means in the field, and those skilled in the art can make adaptive selections according to actual usage needs. This invention does not impose any particular limitations on it.

[0029] This invention provides a nucleic acid molecule comprising a nucleotide fragment encoding the aforementioned protein molecule. The sequence of the nucleotide fragment encoding the protein molecule is determined based on the codon preferences of the protein molecule and the host cell intended for expression. Obtaining the sequence of the nucleotide fragment encoding the protein molecule through reverse translation from the amino acid sequence of the protein molecule is a conventional technique in the art, and those skilled in the art can make adaptive designs according to actual needs; this invention does not impose any particular limitations on it.

[0030] In this invention, the sequence of the nucleotide fragment encoding the protein molecule is preferably as shown in SEQ ID NO:2. In this case, the nucleic acid molecule exhibits good protein expression efficiency in common microbial cells such as Escherichia coli.

[0031] In this invention, those skilled in the art can select the form of the nucleic acid molecule according to the needs of actual application scenarios. Specific examples of the form of the nucleic acid molecule include, but are not limited to, one or more of linear DNA, plasmids, mRNA and circRNA; the nucleic acid molecule can also be integrated into the phage genome.

[0032] In this invention, the construction of the nucleic acid molecule preferably includes: loading a nucleotide fragment encoding the protein molecule onto a plasmid vector to obtain the nucleic acid molecule. Specifically, examples of the plasmid vector include, but are not limited to, the pQE80L expression vector or its derivative expression vector.

[0033] In this invention, the construction of the nucleic acid molecule preferably includes: integrating a nucleotide fragment encoding the protein molecule into a bacteriophage genome to obtain the nucleic acid molecule. Specifically, specific examples of the sources of the bacteriophage genome used for constructing the nucleic acid molecule include, but are not limited to, one or more of T4 bacteriophage, T5 bacteriophage, and T7 bacteriophage.

[0034] This invention provides the use of the aforementioned protein or nucleic acid molecules in the preparation of CBASS defense system antagonists. Specifically, the protein molecule or the protein molecule encoded by the nucleic acid molecule has potential nucleotransferase activity, and the specific defense antagonistic mechanism may include: using nucleoside triphosphates such as ATP and GTP as substrates to synthesize cyclic dinucleotide molecules as competitive ligands, interfering with the recognition and activation of innate immune signals by the host cyclic nucleotide sensing domain or downstream effector modules, thereby antagonizing the CBASS defense system-mediated cytotoxic defense response. It is a highly promising active substance for antagonizing the CBASS defense system.

[0035] In this invention, specific examples of the use of the CBASS defense system antagonist include, but are not limited to: (1) constructing or modifying engineered phages with the ability to antagonize the CBASS defense system; (2) studying CBASS defense mechanisms and viral immune escape mechanisms; and (3) preparing antimicrobial agents that inhibit and / or kill microorganisms containing the CBASS defense system.

[0036] This invention provides a CBASS defense system antagonist, which specifically includes the aforementioned protein molecules or nucleic acid molecules.

[0037] This invention provides the use of the aforementioned protein molecules, nucleic acid molecules, or CBASS defense system antagonists in constructing or modifying engineered phages capable of antagonizing the CBASS defense system. Specifically, examples of methods for constructing or modifying engineered phages capable of antagonizing the CBASS defense system include, but are not limited to, introducing a nucleic acid molecule comprising a nucleotide fragment encoding the protein molecule into the phage genome using genetic engineering techniques to obtain an engineered phage capable of expressing the protein molecule. Specific examples of the engineered phage include, but are not limited to, one or more of T4 phage, T5 phage, and T7 phage.

[0038] This invention provides the use of the aforementioned protein molecules, nucleic acid molecules, or CBASS defense system antagonists in the preparation of antibacterial agents for inhibiting and / or killing microorganisms containing the CBASS defense system. Specifically, the protein molecules, nucleic acid molecules, or CBASS defense system antagonists enhance the infection and lysis efficiency of bacteriophages by antagonizing the CBASS defense system in microbial cells, thereby achieving a more ideal antibacterial effect through synergistic action with the bacteriophages.

[0039] The present invention provides an antibacterial agent comprising the aforementioned protein molecules, nucleic acid molecules, or CBASS defense system antagonists.

[0040] In this invention, the antibacterial agent includes bacteriophages. Specifically, the bacteriophage refers to a type of virus that specifically infects bacteria. Those skilled in the art can select the corresponding bacteriophage to be used in combination with the protein molecule, nucleic acid molecule, or CBASS defense system antagonist according to the microorganism to be controlled. This invention does not impose any particular limitation on the bacteriophage.

[0041] In some specific embodiments, specific examples of the bacteriophage include, but are not limited to, one or more of T4 bacteriophage, T5 bacteriophage, and T7 bacteriophage.

[0042] In this invention, the antibacterial agent includes a delivery carrier for delivering protein molecules, nucleic acid molecules, or CBASS defense system antagonists to cells of microorganisms containing a CBASS defense system. Specifically, examples of the delivery carrier include, but are not limited to, one or more of lipid nanoparticles, polymer nanoparticles, and inorganic nanomaterials.

[0043] The embodiments of the present invention are described in detail below. These embodiments are intended to explain the present invention and should not be construed as limiting the present invention. Where specific techniques or conditions are not specified in the embodiments, they are performed according to the techniques or conditions described in the literature in the art or according to the product instructions. Reagents or instruments used, unless otherwise specified, are all commercially available conventional products.

[0044] Example This embodiment illustrates the screening, preparation, and activity verification of an anti-CBASS protein CsNTase, specifically including: 1. Screening of anti-CBASS protein CsNTase (1) Virus sequence identification and redundancy removal were performed on the metagenomic assembly sequences of deep-sea cold seep environment using the virus identification tools geNomad, VirSorter2, VIBRANT and Cenote-Taker3 to obtain a candidate deep-sea cold seep virus sequence set.

[0045] (2) Prodigal was used to predict and translate open reading frames of candidate deep-sea cold seep virus sequences, and MMseqs2 was used to remove redundancy to obtain deep-sea cold seep virus protein sets.

[0046] (3) The AntiDefenseFinder module in DefenseFinder was used to predict antidefense proteins in the deep-sea cold seep virus protein set, resulting in candidate antidefense protein set I. The protein sequences provided by the dbAPIS antidefense protein database were used as a reference database, and DIAMOND blastp was used to perform sequence similarity search on the deep-sea cold seep virus protein set. The results with sequence consistency > 50%, query coverage > 50%, and E-value < 1e-5 were retained, resulting in candidate antidefense protein set II. The protein sequences provided by the dbAPIS antidefense protein database were used as a reference database, and HMMScan was used to perform HMM profile comparison on the deep-sea cold seep virus protein set. The results with query coverage > 0.5, target coverage > 0.3, domain score > 25, alignment accuracy > 0.70, and E-value < 1e-5 were retained, resulting in candidate antidefense protein set III. The protein sequences provided by the dbAPIS antidefense protein database were used as a reference database, and ProstT5 combined with Foldseek was used to perform structural similarity search on the deep-sea cold seep virus protein set, retaining the results with query coverage > 0.5, target coverage > 0.3, domain score > 25, alignment accuracy > 0.70, and E-value < 1e-5. Hit results with coverage > 0.8, target coverage both > 0.8, and E-value < 1e-10 are used to obtain candidate anti-defense protein set IV; candidate anti-defense protein sets I~IV are merged, and proteins annotated as Anti-CBASS (NTase type) are retained to obtain NTase candidate protein set.

[0047] (4) AlphaFold3 was used to predict the three-dimensional structure of the sequences in the NTase candidate protein set, and TM-align was used to compare the predicted three-dimensional structure with the corresponding reference protein structure matched in the dbAPIS anti-defense protein database. The hit results with TM-score≥0.5 and Identity<30% were retained to obtain the distant NTase protein set.

[0048] like Figure 1 As shown, the distant NTase protein set includes a protein with a TM-score of 0.76 and an Identity of 17.3%. This protein has the same three-dimensional spatial folding backbone as the corresponding Anti-CBASS (NTase type) reference protein and is named the anti-CBASS protein CsNTase. The sequence information of the anti-CBASS protein CsNTase and its encoding gene is shown in Table 1.

[0049] Table 1.

[0050] 2. Preparation of anti-CBASS protein CsNTase (1) The anti-CBASS protein CsNTase encoding gene was cloned into the pQE80L-derived expression vector with kanamycin resistance (by replacing the ampicillin resistance gene in the pQE80L expression vector with the kanamycin resistance gene, the pQE80L-derived expression vector was obtained) to obtain the CsNTase expression plasmid.

[0051] (2) Source Serratia marcescens The type II CBASS defense system of LCT-SM262 (NZ_KE560335.1: 26427-29783, including regions encoding the following proteins: CD-NTase [WP_016928966.1], Cap2 [WP_016928967.1], Cap18 [WP_016928968.1], Cap14 [WP_016928969.1]) was cloned into the pQE82L expression vector with ampicillin resistance to obtain the CBASS defense system expression plasmid.

[0052] (3) According to the plasmid combinations shown in Table 2, introduce the corresponding plasmids. Escherichia coli In BL21(DE3) competent cells, the transformation products were spread onto LB solid medium containing 60 μg / mL ampicillin and 30 μg / mL kanamycin, respectively, and cultured at 37°C until single colonies grew to obtain the corresponding validation strains.

[0053] Table 2.

[0054] (4) Pick single colonies of each validation strain and inoculate them into 5 mL of LB liquid medium containing 60 μg / mL ampicillin and 30 μg / mL kanamycin. Incubate at 37°C with shaking until OD. 600 The concentration was approximately 0.6. IPTG was added at a final concentration of 0.2 mM, and the mixture was then incubated at 37°C for 1 h to obtain the induced expression bacterial culture.

[0055] (5) Take 500 μL of the induced expression culture of each validation strain and mix it evenly with 14.5 mL of LB top soft agar containing agar, ampicillin, kanamycin and IPTG (the final concentration of agar is 0.5%, the final concentration of ampicillin is 60 μg / mL, the final concentration of kanamycin is 30 μg / mL and the final concentration of IPTG is 0.1 mM). Immediately spread it on LB solid medium to obtain phage infection detection plates.

[0056] (6) Take T7 phage, T5 phage and T4 phage and perform serial 10-fold dilutions (T7 phage dilution is 10). -1 ~10 -8 T5 phage dilution was 10. 0 ~10 -7 and T4 phage at a dilution of 10 0 ~10 -7 ), to obtain the phage fluid to be tested.

[0057] (7) Take 4 μL of each dilution of the phage solution to be tested and drop it onto the surface of the phage infection detection plate. After the droplets are absorbed by the culture medium, place the plate in 25°C for 16 h, observe and record the formation of phage plaques, and the results are as follows. Figure 2 As shown.

[0058] Depend on Figure 2 The results show that, in the empty vector control group, the use of T7 phage, T5 phage, and T4 phage effectively controlled the virus. Escherichia coli Treatment of the BL21(DE3) host bacterium consistently resulted in the formation of distinct plaques, indicating that the aforementioned phages could effectively infect this host bacterium. In the CBASS group, T7, T5, and T4 phages were used to treat bacteria that had only undergone CBASS defense system expression plasmid delivery. Escherichia coli Treatment with BL21(DE3) host bacteria significantly inhibited plaque formation, with plaques almost disappearing at high dilutions, indicating that... Serratia marcescens The introduction of the CBASS defense system derived from LCT-SM262 effectively inhibited the infection of the aforementioned phages. In the CBASS+CsNTase group, T7, T5, and T4 phages showed significant resistance to infection. Escherichia coli The infectivity of the BL21(DE3) host bacteriophage was restored, and T7 phages reformed distinct plaques at multiple consecutive dilutions; the number of plaques and the visible dilution range of T5 and T4 phages also increased significantly. Analysis of the above results indicates that the anti-CBASS protein CsNTase provided by this invention can relieve or weaken the inhibitory effect of the CBASS defense system on phage infection, enabling phages to regain their infectivity in host bacteria carrying the CBASS defense system. The anti-CBASS protein CsNTase possesses antagonistic activity against the CBASS defense system.

[0059] Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention. Those skilled in the art can make changes, modifications, substitutions and variations to the above embodiments within the scope of the present invention without departing from the principles and spirit of the present invention.

Claims

1. A protein molecule, characterized in that, The protein molecule includes the amino acid fragment shown in SEQ ID NO:

1.

2. A nucleic acid molecule, characterized in that, The nucleic acid molecule includes a nucleotide fragment encoding the protein molecule of claim 1.

3. The nucleic acid molecule according to claim 2, characterized in that, The sequence of the nucleotide fragment encoding the protein molecule is shown in SEQ ID NO:

2.

4. The use of the protein molecule of claim 1 or the nucleic acid molecule of claim 2 in the preparation of CBASS defense system antagonists, characterized in that, The protein molecule has nucleotide transferase activity.

5. A CBASS defense system antagonist, characterized in that, The CBASS defense system antagonist comprises the protein molecule of claim 1 or the nucleic acid molecule of claim 2.

6. Use of the protein molecule of claim 1, the nucleic acid molecule of claim 2, or the CBASS defense system antagonist of claim 5 in the construction or modification of engineered phages capable of antagonizing the CBASS defense system.

7. Use of the protein molecule of claim 1, the nucleic acid molecule of claim 2, or the CBASS defense system antagonist of claim 5 in the preparation of antibacterial agents.

8. The use according to claim 7, characterized in that, The antibacterial agent is used to inhibit and / or kill microorganisms containing the CBASS defense system.

9. An antibacterial agent, characterized in that, The antibacterial agent comprises the protein molecule of claim 1, the nucleic acid molecule of claim 2, or the CBASS defense system antagonist of claim 5.

10. The antibacterial agent according to claim 9, characterized in that, The antibacterial agent includes one or more of the following technical features: (1) The antibacterial agent includes bacteriophages, and the bacteriophages include one or more of T4 bacteriophage, T5 bacteriophage and T7 bacteriophage; (2) The antibacterial agent includes a delivery carrier for delivering protein molecules, nucleic acid molecules or CBASS defense system antagonists into the cells of microorganisms containing CBASS defense systems; the delivery carrier includes one or more of lipid nanoparticles, polymer nanoparticles and inorganic nanomaterials.